Tevogen Bio (TVGN) Shares 2024 Financing Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
February 14, 2025 1:16 PM ESTWARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (Tevogen Bio Holdings Inc. or Company) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Companys 2024 financing activity at the one year anniversary of being... More
